Cystic Fibrosis Screening Lacks Equity Due to Ancestry Bias in Genetic Panels

Cystic fibrosis (CF) carrier screening is facing significant challenges in accurately identifying at-risk individuals from non-European ancestries, primarily due to a substantial bias in commonly used genetic testing panels. These panels are overwhelmingly designed around variants prevalent in individuals of European descent, leading to a considerable underrepresentation of pathogenic variants found in other populations [1, 2, 12]. This ancestry bias results in significantly lower detection rates and higher residual risk for carriers from diverse ethnic backgrounds, creating a critical health equity gap in genetic screening and reproductive decision-making [1, 12]. The study, published in the European Medical Journal (EMJ), reveals that current CFTR gene testing panels struggle to keep pace with the increasing global population diversity. As migration patterns shift demographics, the range of CFTR variants in circulation expands, diluting the dominance of historically represented European variants. Consequently, fixed variant panels, which were once considered highly sensitive, are becoming less effective over time, particularly in countries with increasingly diverse populations like Australia [1]. Real-world data from international studies illustrate the stark disparities in detection rates. While panels capture around 84-90% of CFTR variants in individuals of European ancestry, this figure plummets to as low as 25-69% in Asian populations, 62-91% in Black populations, 51-55% in Middle Eastern groups, and a mere 17-33% in Pacific Islander groups [1]. This indicates that a substantial proportion of individuals from these backgrounds who are carriers of CF-related mutations may not be identified through current screening protocols. Historically, CF has been most commonly associated with Northern European populations, leading to the development of screening panels that primarily focus on variants prevalent in this demographic [1, 5]. Recommendations from organizations like the American College of Obstetricians and Gynecologists (ACOG) and the American College of Medical Genetics and Genomics (ACMG) initially emphasized pan-ethnic screening for CF but also noted the lower detection rates among non-Caucasian populations [5, 9]. While advancements in next-generation sequencing (NGS) offer the potential for more comprehensive, pan-ethnic screening by identifying a wider array of variants, the implementation of these expanded panels has been slower and less consistent across different healthcare systems [6, 9]. The implications of these screening gaps are profound. For individuals and couples from non-European ancestries, the lack of accurate carrier status information can lead to an increased risk of unknowingly having a child affected by cystic fibrosis. This disparity not only impacts reproductive planning but also contributes to broader health inequities, where access to accurate genetic information and subsequent healthcare is unevenly distributed based on ancestry [1, 12]. The EMJ article underscores the urgent need for the medical and genetic testing industries to address this ancestry bias. This involves developing and implementing more inclusive CFTR variant panels that accurately reflect the genetic diversity of global populations. Strategies such as expanded carrier screening using NGS technology are crucial for ensuring that all individuals, regardless of their ethnic background, receive equitable and comprehensive genetic testing. Without these updates, the promise of genetic screening for conditions like cystic fibrosis will remain unfulfilled for a significant portion of the global population, perpetuating health disparities [1, 6, 9, 12]. Cystic fibrosis itself is a serious genetic disorder caused by mutations in the CFTR gene, leading to the production of thick, sticky mucus that can clog various organs, particularly the lungs and pancreas [1, 5]. While incidence is highest in Northern European populations, CF affects people of all ancestries [1, 5]. Newborn screening for CF has been implemented in many countries, including the US, to improve outcomes [12]. However, disparities in outcomes persist for individuals of Black/African, Asian, Indigenous, and Latino/Hispanic ancestry compared to those of European ancestry, partly due to the limitations of current screening panels [12]. The European Medical Journal (EMJ) is a reputable source for medical news and insights, often reporting on significant developments and research across various therapeutic areas [2, 3, 8]. The publication date of this specific article is June 7, 2026 [1, 3]. This story is relevant globally, as it addresses issues of genetic screening equity and population diversity in healthcare [1, 12].

Frequently Asked Questions

Read Full Story on Quick Digest